Business · 04/08/2025
FDA Reopens Comment Period for Prescription Drug User Fee Act VII Report
The FDA is reopening the comment period for its report on communication through product quality information requests during application review, following a request for additional time to submit comments.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →